President Trump Directs Transparency and Accuracy in Prescription Drug Ads
Impact Score: 2.6
Timeline: No specific deadlines; agencies instructed to take action promptly
Summary: The administration issued a memorandum to improve transparency and accuracy in direct-to-consumer prescription drug advertisements, emphasizing full disclosure of risks to protect patients and maintain trust. The Department of Health and Human Services and FDA are directed to increase risk-related information and enforce truthful advertising. This targets traditional and emerging advertising channels, including social media influencers. The regulation aims to reduce misleading drug promotion and aligns with prior efforts on healthcare price transparency and fair drug pricing.
Key Actions: Vanderbilt University Medical Center should review compliance with new advertising transparency rules; the Department of Health Policy is encouraged to research regulatory impacts; Vanderbilt’s Office of Federal Relations should engage policymakers on drug pricing policy; and the School of Medicine should integrate advertising ethics into curricula. Opportunities exist for Vanderbilt to lead in policy research, education, and collaboration on healthcare transparency.
View Full Report
